Clinical data support safety and tolerability profile of FHD-286, a highly potent,
- selective, allosteric, oral, small molecule inhibitor of BRG1/BRM
- Clinical activity observed in late-line metastatic uveal melanoma includes nine patients with stable disease and one patient with a confirmed partial response
- Foghorn does not plan to advance FHD-286 in uveal melanoma
- Foghorn anticipates initiating a FHD-286 combination study in relapsed/refractory AML during the third quarter of 2023
https://finance.yahoo.com/news/foghorn-therapeutics-announces-clinical-data-110000120.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.